Supera Medical, a Los Gatos, CA-based company advancing a percutaneous ventricular assist device (pVAD), raised $40M in Series D funding.
The round was led by Cormorant Asset Management and The Capital Partnership (TCP), with participation from 415 CAPITAL, AMED Ventures, PA MedTech VC fund, Unorthodox Ventures and Shifamed angel investors.
The company intends to use the funds to expand its currently enrolling OUS studies, plan for its U.S. studies, and prepare for U.S. pivotal study submission.
Led by Dr. Nitin Salunke, President and CEO, Supira Medical is a portfolio company of Shifamed, LLC, focused on developing the Supira System, a percutaneous ventricular assist device for use in high-risk patients undergoing interventional procedures.
With a novel low profile, high continuous flow design, the Supira System aims to provide full hemodynamic support initially for high-risk percutaneous coronary interventions (HRPCI) and subsequently for cardiogenic shock (CS) patients with a single device platform. The system features a 10F profile, designed to minimize vascular complications, and multiple sensors to provide real-time pressure measurements.
The Supira System is for Investigational Use Only and is not for sale in the U.S. or outside the U.S.
FinSMEs
21/11/2023